Synthetic EthR inhibitors boost antituberculous activity of ethionamide

Nature Medicine

Volumn 15, Issue 5, 2009, Pages 537-544

  Willand, Nicolas ^a,b,c,d,e   Dirié, Bertrand ^a,b,c,d   Carette, Xavier ^a,c,d,e   Bifani, Pablo ^f   Singhal, Amit ^f   Desroses, Matthieu ^a,b,c,d,e   Leroux, Florence ^a,b,c,d,e   Willery, Eve ^a,c,d,e   Mathys, Vanessa ^f   Déprez Poulain, Rebecca ^a,b,c,d,e   Delcroix, Guy ^c   Frénois, Frédéric ^b,c,d   Aumercier, Marc ^b,c,d   Locht, Camille ^a,c,d   Villeret, Vincent ^b,c,d   Déprez, Benoit ^a,b,c,d,e   Baulard, Alain R ^a,c,d,e  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d Institut Federatif de Recherche 142   (France)

^e PRIM Pôle de Recherche Interdisciplinaire sur le Médicament   (France)

^f PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BDM 14476; BDM 14486; BDM 14500; BDM 14744; BDM 31343; BDM 31381; ETHIONAMIDE; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETHR INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; FEMALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; TUBERCULOSIS;

MUS; MYCOBACTERIUM TUBERCULOSIS;

EID: 67349287483     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1950     Document Type: Article

References (41)

1. Corbett, E.L. et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163, 1009-1021 (2003).
2. Wells, C.D. et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J. Infect. Dis. 196 Suppl 1, S86-S107 (2007).
3. Cox, H. et al. tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med. 3, e384 (2006).
4. Tomioka, H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr. Pharm. Des. 12, 4047-4070 (2006).
5. Scorpio, A. & Zhang, Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2, 662-667 (1996).
6. Zhang, Y., Heym, B., Allen, B., Young, D. & Cole, S. The catalase peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358, 591-593 (1992).
7. Manjunatha, U.H. et al. Identification of a nitroimidazo-oxazine- specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 103, 431-436 (2006).
8. DeBarber, A.E., Mdluli, K., Bosman, M., Bekker, L.G. & Barry, C.E., III. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 97, 9677-9682 (2000).
9. Baulard, A.R. et al. Activation of the pro-drug ethionamide is regulated in mycobacteria. J. Biol. Chem. 275, 28326-28331 (2000).
10. Qian, L. & Ortiz de Montellano, P.R. Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3. Chem. Res. Toxicol. 19, 443-449 (2006).
11. Dover, L.G. et al. EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. Antimicrob. Agents Chemother. 51, 1055-1063 (2007).
12. Wilson, T.M., Delisle, G.W. & Collins, D.M. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol. Microbiol. 15, 1009-1015 (1995).
13. Boshoff, H.I. & Mizrahi, V. Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides. J. Bacteriol. 182, 5479-5485 (2000).
14. Engohang-Ndong, J. et al. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator. Mol. Microbiol. 51, 175-188 (2004).
15. Weinstein, H.J., Hallett, W.Y. & Sarauw, A.S. The absorption and toxicity of ethionamide. Am. Rev. Respir. Dis. 86, 576-578 (1962).
16. Lees, A.W. Ethionamide and isoniazid in previously untreated cases of pulmonary tuberculosis. Dis. Chest 45, 247-250 (1964).
17. Holdiness, M.R. Neurological manifestations and toxicities of the antituberculosis drugs. A review. Med. Toxicol. 2, 33-51 (1987).
18. Frénois, F., Engohang-Ndong, J., Locht, C., Baulard, A.R. & Villeret, V. Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis. Mol. Cell 16, 301-307 (2004).
19. Dover, L.G. et al. Crystal structure of the TetR/CamR family repressor Mycobacterium tuberculosis EthR implicated in ethionamide resistance. J . Mol. Biol. 340, 1095-1105 (2004).
20. Frénois, F., Baulard, A.R. & Villeret, V. Insights into mechanisms of induction and ligands recognition in the transcriptional repressor EthR from Mycobacterium tuberculosis. Tuberculsis(Edinb.) 86, 110-114 (2006).
21. Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001).
22. Lipinski, C.A. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov. Today Technol. 1, 337-341 (2004).
23. Veber, D.F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615-2623 (2002).
24. Korduláková, J. et al. Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51, 3824-3829 (2007).
25. Vieth, M. et al. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47, 224-232 (2004).
26. Kasim, N.A. et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm. 1, 85-96 (2004).
27. Holdiness, M.R. Clinical pharmacokinetics of the antituberculosis drugs. Clin. Pharmacokinet. 9, 511-544 (1984).
28. Zhu, M. et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb.) 82, 91-96 (2002).
29. Guo, H., Seet, Q., Denkin, S., Parsons, L. & Zhang, Y. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J. Med. Microbiol. 55, 1527-1531 (2006).
30. Zhang, Y., Vilchèze, C. & Jacobs, W.R. Mechanisms of drug resistance in Mycobacterium tuberculosis. in Tuberculosis and the Tubercle Bacillus (eds. Cole, S.T. et al.) 115-140 (American Society for Microbiology, Washington, DC, 2005).
31. Morlock, G.P., Metchock, B., Sikes, D., Crawford, J.T. & Cooksey, R.C. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 47, 3799-3805 (2003).
32. Schaaf, H.S. et al. Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur. J. Clin. Microbiol. Infect. Dis. 26, 203-205 (2007).
33. Phetsuksiri, B. et al. Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J. Biol. Chem. 278, 53123-53130 (2003).
34. Alahari, A. etal. thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS One 2, e1343 (2007).
35. Fajardo, T.T. et al. A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. Am. J. Trop. Med. Hyg. 74, 457-461 (2006).
36. Hastings, R.C., Gillis, T.P., Krahenbuhl, J.L. & Franzblau, S.G. Leprosy. Clin. Microbiol. Rev. 1, 330-348 (1988).
37. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Cryst. 26, 795-800 (1993).
38. Winn, M.D., Isupov, M.N. & Murshudov, G.N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. D Biol. Crystallogr. 57, 122-133 (2001).
39. Collaborative-Computational-Project-Number-4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
40. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
41. Snewin, V.A. etal. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect. Immun. 67, 4586-4593 (1999).